- Home
- PRME vs EYPT Comparison
PRME vs EYPT Comparison
Compare PRME & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | EYPT |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 1.1B |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PRME | EYPT |
|---|---|---|
| Price | $3.37 | $12.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.56 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $3.91 |
| 52 Week High | $6.94 | $19.11 |
Technical Indicators
Market Signals| Indicator | PRME | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 36.11 |
| Support Level | $3.19 | $12.47 |
| Resistance Level | $4.74 | $14.54 |
| Average True Range (ATR) | 0.24 | 0.78 |
| MACD | -0.04 | -0.21 |
| Stochastic Oscillator | 7.32 | 10.32 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.